ZA99723B - Recombinant proteins derived from HGF and MSP. - Google Patents

Recombinant proteins derived from HGF and MSP.

Info

Publication number
ZA99723B
ZA99723B ZA9900723A ZA99723A ZA99723B ZA 99723 B ZA99723 B ZA 99723B ZA 9900723 A ZA9900723 A ZA 9900723A ZA 99723 A ZA99723 A ZA 99723A ZA 99723 B ZA99723 B ZA 99723B
Authority
ZA
South Africa
Prior art keywords
recombinant proteins
msp
hgf
proteins derived
deriving
Prior art date
Application number
ZA9900723A
Other languages
English (en)
Inventor
Enzo Medico
Paolo Michieli
Chlara Collesi
Gianfranco Caselli
Paolo Comoglio
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of ZA99723B publication Critical patent/ZA99723B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA9900723A 1998-01-30 1999-01-29 Recombinant proteins derived from HGF and MSP. ZA99723B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98MI000179A ITMI980179A1 (it) 1998-01-30 1998-01-30 Proteine ricombinanti derivate da hgf e msp

Publications (1)

Publication Number Publication Date
ZA99723B true ZA99723B (en) 1999-07-29

Family

ID=11378771

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900723A ZA99723B (en) 1998-01-30 1999-01-29 Recombinant proteins derived from HGF and MSP.

Country Status (14)

Country Link
US (1) US6551991B1 (de)
EP (1) EP1049778B1 (de)
JP (1) JP4478329B2 (de)
AT (1) ATE335080T1 (de)
AU (1) AU740490B2 (de)
CA (1) CA2319211C (de)
DE (1) DE69932592T2 (de)
ES (1) ES2270581T3 (de)
HU (1) HU226717B1 (de)
IL (2) IL137564A0 (de)
IT (1) ITMI980179A1 (de)
NZ (1) NZ506005A (de)
WO (1) WO1999038967A2 (de)
ZA (1) ZA99723B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499896A1 (en) * 2002-10-07 2004-04-22 Genentech, Inc. Hepatocyte growth factor variants
WO2004108144A1 (ja) * 2003-06-06 2004-12-16 Kringle Pharma Inc. 細胞含有製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DK0642580T3 (da) * 1992-05-18 2002-12-23 Genentech Inc Hepactocytvækstfaktorvarianter
CA2117893A1 (en) 1992-05-18 1993-11-25 Paul J. Godowski Variant dimers for receptor activation
EP0661993B1 (de) * 1992-09-16 1997-05-07 Genentech, Inc. Schutz gegen leberschäden mit hgf

Also Published As

Publication number Publication date
AU2424599A (en) 1999-08-16
DE69932592D1 (de) 2006-09-14
HU226717B1 (en) 2009-07-28
WO1999038967A3 (en) 1999-09-16
DE69932592T2 (de) 2007-08-09
EP1049778B1 (de) 2006-08-02
WO1999038967A2 (en) 1999-08-05
CA2319211C (en) 2010-10-26
AU740490B2 (en) 2001-11-08
IL137564A0 (en) 2001-07-24
ATE335080T1 (de) 2006-08-15
HUP0104598A1 (hu) 2002-03-28
IL137564A (en) 2007-06-17
US6551991B1 (en) 2003-04-22
HUP0104598A3 (en) 2003-09-29
NZ506005A (en) 2003-06-30
ITMI980179A1 (it) 1999-07-30
JP2002501745A (ja) 2002-01-22
EP1049778A2 (de) 2000-11-08
CA2319211A1 (en) 1999-08-05
ES2270581T3 (es) 2007-04-01
JP4478329B2 (ja) 2010-06-09

Similar Documents

Publication Publication Date Title
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
FI972086A7 (fi) Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
BR9407956A (pt) Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
IL145381A0 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
GB9415167D0 (en) Improvements relating to cancer therapy
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
NO20004911D0 (no) Antitumormiddel
GR3026602T3 (en) Morphogen-induced liver regeneration.
MX9800945A (es) Uso de griseofulvina para inhibir el crecimiento de canceres.
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
BR9808221A (pt) Método de tratamento de tumor.
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
ATE285247T1 (de) Krebstherapie mit lymphotoxin
IL137564A0 (en) Recombinant proteins derived from hgf and msp
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE232398T1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung